AKLI: Akili, Inc. - Summary | Jitta

Akili, Inc.

NASDAQ:AKLI

Notice
Stock data is unavailable or the company’s delisted.
Price
$0.43
Loss Chance
58.0%
1.17JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
Sorry, the data is not yet available for this stock.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (32)
Recent Business Performance (72)
Financial Strength (31)
Return to Shareholders (0)
Competitive Advantage (26)
Jitta Signs
Recent Business PerformanceEarning Growth Last Year
Cash Conversion CycleLess than 30 days
Recent IPOLess than 3 years
Operating MarginInconsistent
New Share IssuedMore than 50% in 5 years
CapExVery High
Key Stats
Jitta Score
Jitta Line
1.17
100.00%
3.06
148.42%
Health Care Technology
4.56
100.00%
5.26
26.47%
4.17
94.67%
COMPANY DESCRIPTION
Akili, Inc., a digital medicine company, develops cognitive treatments through game-changing technologies. The company provides EndeavorRx, a computer-based testing for cognitive dysfunction across several neurology and psychiatry indications, including attention-deficit hyperactivity disorder, depressive disorder, autism spectrum disorder, multiple sclerosis, and other neuroinflammatory diseases. It also offers selective stimulus management engine mechanism to activate the fronto-parietal cortex area in the brain; body brain trainer for attention, impulsivity, working memory, and goal management; and spatial navigation engine for spatial navigation, memory, and planning and organization. The company was founded in 2011 and is headquartered in Boston, Massachusetts. As of July 2, 2024, Akili, Inc. operates as a subsidiary of Virtual Therapeutics Corp.